Development of the Feldan Shuttle platform / Amélioration de l’activité cytotoxique des cellules Natural Killer (NK) en utilisant une stratégie d’invalidation de gène(s) cible(s) par technologie CRISPR

Feldan Therapeutic developed the Feldan Shuttle platform, a breakthrough peptide-based delivery method that allows the introduction of foreign proteins inside cells. The Feldan Shuttle overcomes delivery obstacles in therapeutic context by providing a safe and highly efficient approach that is associated with low regulatory burden. The Shuttle platform can transfer active nucleases and transcription factors inside several types of cells; moreover, preliminary results in rodents suggest that the Shuttle has a promising potential for in vivo applications.
The Mitacs project described herein will allow the characterization of the in vivo and ex vivo capabilities of the Shuttle platform while allowing the development of more active Shuttles, three elements that will promote the growth of Feldan and will permit to carry forward its clinical aspirations. TO BE CONT’D

Faculty Supervisor:

Frédéric Calon;Elie Haddad

Student:

Partner:

Feldan Therapeutics

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology; Professional, scientific and technical services

University:

Université de Montréal; Université Laval

Program: